Immunotherapy biotech Jounce Therapeutics sets terms for $75 million IPO – Renaissance Capital
|
Immunotherapy biotech Jounce Therapeutics sets terms for $75 million IPO
Renaissance Capital Jounce Therapeutics, a early-stage biotech developing T-cell immuno-oncology therapies with Celgene, announced terms for its IPO on Tuesday. The Cambridge, MA-based company plans to raise $75 million by offering 5.4 million shares at a price range of … |
